Better Health for All

PhenixFIN Corporation (PFX.US), identified as Envision Healthcare in one article, provides extensive healthcare services, including 19 million patient encounters, 8 million emergency department encounters, 6 million radiology reads, 2 million inpatient encounters, 2 million anesthesia cases, and 120,000 newborn deliveries.

The company has developed two new CMS-approved quality measures for palliative care and congestive heart failure, contributing to a total of six CMS measures in the past three years. It also participates in 30 investigator-initiated and Envision-initiated studies, resulting in 116 publications. These activities indicate a significant positive health impact, aligning with a score of 30 for health_impact_core. However, Envision's aggressive out-of-network pricing strategy, which led to significant financial issues and susceptibility to the No Surprises Act, suggests a high percentage of revenue from activities with negative health outcomes, warranting a score of -100 for harmful_revenue_share and -100 for price_accessibility. The company faced lawsuits alleging violations of California's corporate practice of medicine, including lay influence over clinical decisions and physician billing control, and was accused of understaffing emergency rooms and violating EMTALA. These issues, along with a 75% decrease in EBITDA from $1 billion in 2020 to $250 million in 2022, indicate significant negative health externalities, scoring -90. The company's safety record is mixed; while it operates a Patient Safety Organization and a Qualified Clinical Data Registry, and reports wrong-site block rates between 0.008% and 0.080%, left-without-being-seen rates between 1.97% and 4%, and central line days between 0.23% and 2.0%, these rates are not directly comparable to the rubric's 'per million users' threshold. However, the existence of these incidents, combined with regulatory scrutiny, suggests a significant safety concern, scoring -80. Envision provided care to over 5,000 patients in the Dominican Republic, Honduras, Jordan, and Zimbabwe, and supplied medical aid to Ukraine, indicating efforts to reach vulnerable populations, scoring -60. The company's participation in 30 studies and 116 publications suggests some investment in health innovation, scoring -10. Its global health initiatives and support for Spanish-speaking individuals, along with new employee resource groups, indicate health equity programs, scoring -60. The company offers a clinician wellness program, including mental health services, peer support, and crisis debriefs, scoring -60 for healthcare_workforce_support and -60 for mental_health_initiatives. During public health emergencies, Envision cared for 1/10 of hospitalized COVID-19 patients, provided testing, adjusted hospital protocols, and supplied medical aid to Ukraine, scoring -70 for global_health_crisis_response. The focus on opioid alternatives and 99% adherence to MIPS opioid measures indicates addiction mitigation efforts, scoring -60. The company's participation in 30 investigator-initiated and Envision-initiated studies, without specific ethical conduct details, scores -70 for clinical_trial_ethics.

Fair Money & Economic Opportunity

The provided investor overview from PhenixFIN Corporation's website does not contain any data relevant to the metrics for Fair Money & Economic Opportunity.

The article focuses on the company's financial performance, investment strategies, and corporate structure, rather than its social impact or lending practices related to fair money and economic opportunity.

Honest & Fair Business

The company has not reported any regulatory fines in the past three years.

It self-identified a non-compliance with a tax distribution requirement for the tax year ended September 30, 2023, notified the IRS, and declared a special dividend to rectify it. No financial restatements have been mentioned in the past five years. A whistleblower policy is in place, allowing anonymous reporting via phone or email to the Chief Compliance Officer, and concerns are investigated by the CCO in consultation with outside counsel, with the Audit Committee addressing specific types of concerns. The company has adopted a formal business code of conduct and ethics that governs key officers, requiring disclosure of conflicts of interest to the CCO, and approvals or waivers must be considered by disinterested directors. This policy is FCPA-compliant and covers all markets, but there is no evidence of training frequency or effectiveness metrics. The company uses third-party valuation firms to assist in the valuation of its portfolio investments, but the extent of independent verification of ethical claims is not specified. The board is stated to have approximately 60% independent directors.

Kind to Animals

The provided article explicitly states that there is no information relevant to any of the KPIs for the 'Kind to Animals' value.

Therefore, no KPIs can be scored based on the available evidence.

No War, No Weapons

PhenixFIN Corporation is a specialty finance company that invests in other businesses. Evidence indicates that PhenixFIN has provided a senior secured loan to WHI Global and partnered to refinance MB Precision Investment Holdings LLC.

Both WHI Global and MB Precision are described as being involved in aerospace, defense, and industrial applications or sectors. While this demonstrates an association with companies that operate in the defense sector and potentially utilize dual-use technology, the provided articles do not offer any quantitative data regarding the percentage of PhenixFIN's own revenue derived from these defense-related investments. Furthermore, there is no specific data on the scope of R&D investment in dual-use technologies by PhenixFIN or its investee companies, nor any information on sales to embargoed regimes, peacebuilding initiatives, or other relevant ethical considerations. Therefore, no KPIs can be scored based on the available evidence.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles regarding PhenixFIN Corporation's performance or practices related to Respect for Cultures & Communities.

The articles primarily focus on financial performance, investment strategies, and shareholder ownership, and explicitly state the absence of data relevant to social or community impact metrics.

Safe & Smart Tech

The provided articles are financial reports for PhenixFIN Corporation (PFX.US) and explicitly state that they contain no data relevant to the 'Safe & Smart Tech' value, including information on data protection, cybersecurity, or responsible AI practices.

Therefore, no assessment can be made against any of the KPIs for this value.

Zero Waste & Sustainable Products

No specific, concrete data points for PhenixFIN Corporation (PFX.US) related to waste management, product sustainability, or circular economy practices were found in the provided articles. The articles either pertain to a different entity (Phoenix Group, an investment firm)

or offer general advice and case studies not attributed to PFX.US. As a specialty finance company, PFX.US's operations would primarily involve office waste, but no data on this or any other relevant KPI was provided.